Vokes EE - Search Results

1

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. Among authors: vokes ee. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.

2

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study.

Runge-Morris MA, Kies MS, Vokes E, Blough R, Weidner L, Knop R, Rowland K. Runge-Morris MA, et al. Invest New Drugs. 1989 Jul;7(2-3):269-73. doi: 10.1007/BF00170872. Invest New Drugs. 1989. PMID: 2793384

3

Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.

Lad T, Rosen F, Sciortino D, Brockstein B, Keubler JP, Arietta R, Vokes E. Lad T, et al. Invest New Drugs. 2000 Aug;18(3):261-3. doi: 10.1023/a:1006481924287. Invest New Drugs. 2000. PMID: 10958595 Clinical Trial.

4

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Cohen EE, et al. Among authors: vokes ee. J Clin Oncol. 2003 May 15;21(10):1980-7. doi: 10.1200/JCO.2003.10.051. J Clin Oncol. 2003. PMID: 12743152 Clinical Trial.

5

Therapeutic options for laryngeal cancer.

Vokes EE, Stenson KM. Vokes EE, et al. N Engl J Med. 2003 Nov 27;349(22):2087-9. doi: 10.1056/NEJMp038171. N Engl J Med. 2003. PMID: 14645634 No abstract available.

6

Cetuximab in cancers of the lung and head & neck.

Kim ES, Vokes EE, Kies MS. Kim ES, et al. Among authors: vokes ee. Semin Oncol. 2004 Feb;31(1 Suppl 1):61-7. doi: 10.1053/j.seminoncol.2003.12.016. Semin Oncol. 2004. PMID: 14981582 Review.

7

The expanding role of systemic therapy in head and neck cancer.

Cohen EE, Lingen MW, Vokes EE. Cohen EE, et al. Among authors: vokes ee. J Clin Oncol. 2004 May 1;22(9):1743-52. doi: 10.1200/JCO.2004.06.147. J Clin Oncol. 2004. PMID: 15117998 Review.

8

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Herbst RS, et al. Among authors: vokes ee. J Clin Oncol. 2005 Aug 20;23(24):5578-87. doi: 10.1200/JCO.2005.07.120. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009949 Clinical Trial.

9

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, Witt ME, Haraf DJ. Salama JK, et al. Among authors: vokes ee. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):382-91. doi: 10.1016/j.ijrobp.2005.07.005. Epub 2005 Oct 5. Int J Radiat Oncol Biol Phys. 2006. PMID: 16213104

10

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Cohen EE, et al. Among authors: vokes ee. Clin Cancer Res. 2005 Dec 1;11(23):8418-24. doi: 10.1158/1078-0432.CCR-05-1247. Clin Cancer Res. 2005. PMID: 16322304 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

559 results

Search Page